Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D’s Standard Deductible, Copays To Drop In 2014

This article was originally published in The Pink Sheet Daily

Executive Summary

With dropping drug expenses in Part D, CMS’ annual call letter for Part D drug plans proposes reducing beneficiary expenses for the standard plan in 2014, the first drop since the program began.

You may also be interested in...



Part D 2014 Draft Call Letter Addresses Automatic Rx Refills, Drug Safety Issues

CMS instructions to Part D sponsors cite elimination of waste as a reason to require plans to confirm members want a refill. Draft call letter also addresses expanding drug utilization reviews beyond opioids, added controls on compounded drugs.

Rx Spending Continues To Lag Overall Health Growth; New Drugs Have Positive Impact in 2011 Data

Prescription drug spending modestly increased in 2011 but continues to lag historically slow rates of overall health spending growth. But it could have been worse: government actuaries cite spending on new brands as driving what growth there is.

Medicare Part D Monthly Premiums To Hold Steady For Another Year

CMS projects that monthly premiums for basic coverage in the Part D prescription drug plan will hold at $30 in 2013, essentially the same rate paid on average by beneficiaries in 2012 and 2011.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS075282

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel